Apimeds Pharmaceuticals US (APUS) Accounts Payables (2023 - 2025)

Apimeds Pharmaceuticals US has reported Accounts Payables for 3 years, with the latest figure at $918649.0 in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 55.39% year-over-year to $918649.0; the trailing twelve-month figure through Dec 2025 stood at $918649.0 (up 55.39% YoY), and the FY2025 full-year result was $918649.0, up 55.39% from the prior year.
• Accounts Payables for Q4 2025 stood at $918649.0, up from $567633.0 in the prior quarter.
• The five-year high for Accounts Payables was $935203.0 in Q1 2025, with the low at $54438.0 in Q4 2023.
• Historically, Accounts Payables has averaged $531042.0 across 3 years, with a median of $579412.0 in 2024.
• Annual changes were most pronounced in 2024 — Accounts Payables soared 985.99% — and 2025, when it surged 55.39%.
• Apimeds Pharmaceuticals US's Accounts Payables stood at $54438.0 in 2023, then soared by 985.99% to $591191.0 in 2024, then surged by 55.39% to $918649.0 in 2025.
• The last three Accounts Payables figures came in at $918649.0 (Q4 2025), $567633.0 (Q3 2025), and $119138.0 (Q2 2025), per Business Quant data.